From Biomarkers to Bedside: Why the Future of Precision Medicine Depends on Seeing the Whole Picture

Imagine spending five years developing a therapy that could change a patient's life—only to learn your clinical trial can't support FDA approval because no one collected the right samples early enough to prove it works.

It's the kind of setback that can delay promising treatments for years and cost millions of dollars—not because the science failed, but because the development process did.

Precision medicine enables a move away from a ‘one-size-fits-all’ approach to healthcare. It creates the possibility of delivering tailored therapies specific to each patient's biology. It’s the ability to ‘deliver the right treatment to the right patient at the right time.’

Yet behind the breakthrough lies an increasingly complex reality. Developing a precision therapy requires researchers, diagnostic developers, clinicians, regulatory specialists, manufacturers, and commercial teams to work together over years of development. Decisions made early in that process can influence everything that follows, from clinical trial design and regulatory approval to reimbursement and patient care.

As precision medicine reshapes healthcare, it is also transforming what life science professionals need to know.

"The biggest challenge in precision medicine right now is that not enough professionals understand how all the pieces of the development process integrate together," says Jelveh Lameh, PhD, Head of Translational Science at Zai Lab and instructor with UC San Diego's Division of Extended Studies. 

In an effort to address this skills gap, Lameh and Larry Mimms, PhD, both longtime life sciences executives and instructors with Extended Studies, developed the new Precision Medicine and Companion Diagnostics course. 

Together they hope the expanded awareness of the entire precision medicine development cycle can help biotechnology professionals avoid the types of costly delays that come with failing to anticipate downstream needs. Millions of dollars, years of work and countless patient lives are at stake. 

Precision Medicine Requires More Than Scientific Discovery

Most professionals entering biotechnology develop deep expertise in one area. Some become specialists in biomarker discovery. Others focus on diagnostics, pharmaceutical development, clinical trials, or regulatory affairs. Graduate programs prepare scientists exceptionally well for their individual disciplines.

But what is rarely taught is how each discipline influences the next.

"I would argue that most people in pharma have never actually seen their drug from the beginning all the way through approval and marketing," said Mimms. "The timelines are simply too long."

A therapy can take a decade or more to move from discovery to market. During that time, hundreds of professionals contribute specialized knowledge, often without fully understanding the challenges their colleagues face further along the development pathway. Expecting any specialist to understand every specialty would be untenable. Instead, what’s needed are professionals who understand how those specialties connect.

"The idea is really to integrate all these pieces and see how they come together, rather than having a narrow-minded approach from your own background," said Lameh. 

She compares the process to assembling a puzzle. "If you understand the full picture of the puzzle," she says, "you can put your own piece together better, even if that's only your little section."

Bridging the Skills Gap in Drug Development

One of the defining characteristics of precision medicine is that seemingly small decisions can have enormous consequences years later.

A clinical team may decide which patient samples to collect during an early-phase trial. A biomarker researcher may choose which molecular signatures to investigate. A diagnostic developer may select one testing platform over another. Those decisions can determine whether a therapy ultimately succeeds—or whether years of work must be repeated.

"If you don't think about those questions ahead of time, you may get to the end and realize you have to do the trial all over again," explained Lameh.

She has witnessed the consequences firsthand. In one project, an otherwise promising therapy failed because the clinical endpoint had not been defined appropriately for regulatory review. Although the treatment later proved successful under a redesigned study, correcting the mistake required years of additional development.

"The same drug passed when the clinical trial was redone," she said. "But it was three years and millions of dollars later."

That experience has shaped the way she thinks about precision medicine. Rather than simply answering today's scientific questions, researchers must anticipate tomorrow's.

"Sometimes you need to ask questions even if you don't know whether you’ll ever need the answer or not," she explained. "Collect the data. Collect the samples. Be able to ask those questions later."

Why Biomarkers, Diagnostics, and Regulatory Strategy Must Work Together

Another challenge is that much of the knowledge needed to navigate the precision medicine discovery process isn't taught in graduate school. Instead, professionals learn it over years of industry experience—often only after costly mistakes have already been made.

Avoiding such mistakes often requires professionals to adopt practices that might seem excessive or redundant to them, but veterans of the industry are learning just how valuable that extra diligence really is. 

"I'm all about the documentation," said Mimms. “Instead of viewing documentation as administrative paperwork, I try to teach students to see it as the thread connecting every stage of development. That's something they never taught you in college before.”

The level of additional thoughtfulness required also extends to design controls, regulatory strategy, clinical planning, cross-functional collaboration, and commercialization.

For Lameh, the hard-won lesson she imparts upon her students is to become better collaborators. "As a bench scientist or someone working in translational medicine, you know there are other nuances that should be accounted for," she said. "So talk to your regulatory and clinical team ahead of time. Talk to the diagnostic company. Get everybody to bring their expertise to the table and plan ahead for every stage."

Building Precision Medicine Expertise Through Real-World Learning

The upcoming Precision Medicine and Companion Diagnostics course was developed by Lameh and Mimms, with support from additional translational medicine and regulatory experts, to help industry professionals better understand the full journey of developing precision medicine treatments. 

"We're trying to give people the bigger picture," Mimms says.

Participants explore the entire product development journey through real-world case studies, FDA documentation, regulatory examples, and collaborative discussions. By analyzing successful product approvals and the decisions behind them, participants will gain insight into challenges they may not yet have encountered in their own careers.

Beyond the learning, for Lameh, the course is valuable in the way it also creates opportunities for conversation. "We want them to ask specific questions and get direct guidance from experts in the field," she explained.

Both Mimms and Lameh recognize that many professionals currently acquire this perspective only after years of working across multiple projects, but they hope that a course such as this can dramatically shorten the learning curve.

Preparing the Next Generation of Precision Medicine Leaders

Precision medicine promises to transform healthcare by making treatment more personal, more targeted, and more effective.

Yet, as healthcare becomes increasingly personalized, success will depend not only on scientific innovation but also on professionals who understand how discoveries become therapies.

Researchers must think beyond the laboratory. Diagnostic developers must understand clinical strategy. Commercial teams must recognize how development choices affect reimbursement and adoption. And regulatory specialists must appreciate the scientific decisions that shape submissions. No single person can become an expert in every discipline, but everyone benefits from understanding how their work fits into the larger system.

For Mimms, that's the ultimate value of the course. "They will have a renewed appreciation for the entire process," he said. “It will help them make more forward-thinking decisions that will hopefully have positive ripple effects all the way through to approval and reimbursement.”

"So many intelligent professionals play a part in developing these treatments, and I think there’s tremendous opportunity in helping them see how their work fits into the larger picture," Lameh added. 

Ultimately, the future of precision medicine depends on those professionals who can think across disciplines, anticipate challenges before they emerge, and understand how every decision—from biomarker discovery to bedside care—shapes the journey that follows.

Visit the Precision Medicine and Companion Diagnostics course page to learn more and register.